Therapeutics News and Research

RSS

Cannabis compound may stop breast cancer spreading

American researchers have found that a compound found in cannabis may stop breast cancer spreading throughout the body.

20 Nov 2007

Super-tiny structures for biomedical research

The University of Massachusetts Amherst is host to a new nanomedicine institute focused on developing super-tiny structures for biomedical research.

19 Nov 2007

Cannabis compound may stop the spread of breast cancer cells

A compound found in cannabis may prove to be effective at helping stop the spread of breast cancer cells throughout the body.

19 Nov 2007

Pfizer to acquire Coley Pharmaceutical Group

Pfizer has announced that it has entered into an agreement to acquire Coley Pharmaceutical Group, a publicly-held biopharmaceutical company specializing in vaccine adjuvant technology and a new class of immunomodulatory drug candidates designed to fight cancers, allergy and asthma disorders, and autoimmune diseases.

19 Nov 2007

University of Illinois at Chicago receives $2.2 million grant to develop drugs to suppress cocaine cravings

The University of Illinois at Chicago College of Pharmacy has received a $2.2 million federal grant to develop therapeutics to suppress the cravings of cocaine addicts.

19 Nov 2007

How inhibitor-of-apoptosis chemicals kill tumors

Chemical compounds specially designed to neutralize proteins that would otherwise allow tumor cells to cheat death have been recognized for some time by scientists as a promising new avenue for cancer therapy.

16 Nov 2007

WaferGen and University of Pittsburgh to collaborate on SmartChip

WaferGen Biosystems, Inc. has announced that it has established a research collaboration with the University of Pittsburgh Medical School to have it serve as the alpha test site for WaferGen's SmartChip Real-Time PCR System.

14 Nov 2007

Pfizer and Nektar resolve outstanding Exubera contractual issues

Pfizer and Nektar Therapeutics have announced that the two companies have resolved all outstanding contractual issues in connection with Exubera and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development.

14 Nov 2007

Factor key to severity of community-associated methicillin-resistant staph infections identified

Newly described proteins in drug-resistant strains of the Staphylococcus aureus bacterium attract and then destroy protective human white blood cells - a key process ensuring that S. aureus survives and causes severe disease, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

13 Nov 2007

Turmeric back in the fight against cancer

Scientists have known for some time that turmeric, a key flavour in Indian curry, has anti-cancer properties.

7 Nov 2007

Microcarrier patent to be auctioned

Sedum Laboratories, Inc., formerly of Mansfield, Mass., is auctioning its U.S. Patent #6,645,525 titled "Ionically Formulated Biomolecule Microcarriers."

6 Nov 2007

Modified Curcumin demonstrates even greater tumor suppressive properties

Curcumin, the yellowish component of turmeric that gives curry its flavor, has long been noted for its potential anti-cancer properties.

6 Nov 2007

More effective method of treating high blood pressure

Scientists at Robarts Research Institute have developed a simplified and more effective method of treating high blood pressure.

6 Nov 2007

Review of controversy surrounding the human papillomavirus (HPV) vaccine

In an article appearing in the current issue of Clinical Pharmacology & Therapeutics, experts from the University of Pennsylvania Center for Bioethics and Johns Hopkins Berman Institute of Bioethics review the controversy surrounding the human papillomavirus (HPV) vaccine debate, and its effects on ethical and public health issues.

2 Nov 2007

Therapeutic gene expression can be sustainable for 1 year

Researchers at the Board of Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center have shown for the first time that it is possible to sustain therapeutic gene expression in the central nervous system for up to a year, even in the presence of an anti-viral immune response mechanism that is normally present in humans.

28 Oct 2007

Emerging cancer therapies and novel targets

What are the cancer drugs of tomorrow and how will they be developed? At the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, researchers will present some answers to these and other pressing questions regarding emerging cancer therapeutics.

25 Oct 2007

Stanford researchers get precise picture of cell target for drugs

More than half of all drugs given to patients work by targeting a particular type of "docking station," or receptor, found on body cells, to steer the cell's machinery toward healing an illness.

25 Oct 2007

Promising new tuberculosis drug given special status

Approximately one-third of the world's population is infected with Mycobacterium tuberculosis, the bacterium that causes TB, and an estimated 1.6 million people died of the disease in 2005.

25 Oct 2007

Amazon jungle plant compound blocks tissue destruction

Scientists at Case Western Reserve University's School of Medicine have published in the Journal of Inflammation a remarkable discovery with a natural product derived from the Amazon rainforest.

24 Oct 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007